An antimetastatic role for decorin in breast cancer

Silvia Goldoni1, Daniela G Seidler, Jack Heath

  • 1Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Insights

Decorin effectively inhibits breast cancer cell growth and metastasis. This small leucine-rich proteoglycan shows therapeutic potential by reducing primary tumor growth and preventing lung metastasis, unlike the ErbB2 inhibitor AG879.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Decorin is a small leucine-rich proteoglycan that negatively regulates ErbB receptor tyrosine kinase signaling.
  • ErbB2 overexpression is implicated in mammary carcinoma progression and metastasis.

Purpose of the Study:

  • To investigate the therapeutic potential of decorin against ErbB2-overexpressing breast cancer.
  • To compare the efficacy of decorin with AG879, an ErbB2 kinase inhibitor, in preclinical models.

Main Methods:

  • In vitro cell proliferation, anchorage-independent growth, and apoptosis assays.
  • In vivo studies using orthotopic mammary carcinoma xenografts in mice.
  • Systemic administration of decorin and AG879, individually and in combination.
  • Assessment of primary tumor growth, metabolism, ErbB2 levels, and lung metastasis using species-specific DNA detection.

Main Results:

  • Decorin significantly inhibited breast cancer cell proliferation and induced apoptosis in vitro.
  • Both decorin and AG879 reduced primary tumor growth and metabolism by approximately 50% in vivo, with no observed synergism.
  • Decorin specifically reduced ErbB2 levels in tumors and, crucially, prevented lung metastasis.
  • AG879 demonstrated no effect on metastasis.

Conclusions:

  • Decorin is a potent inhibitor of breast cancer growth and metastasis.
  • Decorin exhibits a dual therapeutic effect by targeting primary tumor growth and preventing metastatic spread.
  • Decorin represents a promising therapeutic agent for breast cancer, particularly in cases of ErbB2 overexpression.